A new study has found that popular weight loss injections not only help people shed pounds but may also protect the heart.
Researchers at the Technical University of Munich (TUM), together with colleagues from Harvard Medical School, reported that medications such as semaglutide (sold under the brand names Ozempic and Wegovy) and tirzepatide (Mounjaro) could reduce the risk of hospitalization or death from heart failure by more than 40%.
The findings, published in the Journal of the American Medical Association (JAMA), add growing evidence that drugs initially developed for diabetes and obesity may have far-reaching health benefits.
The study focused on patients with heart failure with preserved ejection fraction (HFpEF). This condition, often linked to obesity and diabetes, affects over 30 million people worldwide.
In HFpEF, the heart still pumps blood normally, but stiffened heart muscle makes it harder for the heart to fill properly. This leads to breathlessness, fatigue, and swellingβsymptoms that can severely limit quality of life.
βTogether with our colleagues at Harvard, we created a strong evidence base showing these drugs have protective effects in heart failure,β said Professor Heribert Schunkert, Director of the Department of Cardiovascular Diseases at TUMβs German Heart Center.
βOur analysis of nearly 100,000 patients is a robust foundation for considering new treatment approvals.β
The researchers reviewed three large U.S. health insurance databases, covering patients far beyond traditional clinical trial groups.
They compared semaglutide and tirzepatide with other diabetes medications that have not been shown to reduce heart failure risks.
Results were striking: patients who received either of the two injections were over 40% less likely to be hospitalized for heart failure or to die compared to those who used the other drug.
βThis is especially important because there are only a few effective treatments available for HFpEF today,β explained Dr. Nils KrΓΌger, lead author of the study.
βWith obesity and diabetes on the rise, these drugs could significantly reduce hospitalizations and improve lives.β
One of the unique strengths of this study is its scale. By analyzing a population 20 times larger than typical clinical trials, the researchers were able to capture how the drugs perform in real-world settingsβnot just under controlled trial conditions.
βThis type of big data approach complements traditional trials and ensures that new discoveries benefit patients sooner,β noted Professor Schunkert.
In Germany, upcoming policies such as the Health Data Utilization Act are expected to make anonymized health insurance records more widely available for research while protecting patient privacy.
Despite the positive findings, cardiology societies still recommend caution. While the results are promising, long-term data are limited, and regulators will need to carefully evaluate risks, side effects, and costs.
Common side effects of these drugs include nausea, stomach discomfort, and digestive issues.
Rare but serious reactions can also occur.Still, the new analysis suggests that weight loss injections may play a dual role: supporting weight management and reducing cardiovascular risks.
For millions living with HFpEF, this could mark an important shift in available treatment options.
A Natural Boost for Healthy Weight and Sleep
Alongside medical treatments, lifestyle and wellness support play a huge role in long-term health. Thatβs where Sleep Lean comes in.
This patented, all-natural formula uses eight carefully chosen ingredients to fight stubborn weight linked to poor sleep and late-night cravings.
By improving deep, restful sleep and balancing metabolism, Sleep Lean helps the body burn fat more efficiently overnight. Itβs a gentle, U.S.-crafted solution for anyone seeking natural weight support.
π Discover Sleep Lean here
